Akari Therapeutics Announces Filing for New Patent for Novel ADC Platform Utilizing Spliceosome Payload PH1 for the Treatment of Cancer
Akari Therapeutics (Nasdaq: AKTX) has filed a provisional patent application with the USPTO for its novel antibody drug conjugate (ADC) platform utilizing the spliceosome payload PH1 for cancer treatment. The patent covers the platform's unique mechanism of modulating alternative splicing within cancer cells.
The technology targets cancer cells' ability to hijack alternative splicing (AS) processes, which affects tumor formation, growth, and metastasis. The PH1 payload demonstrates potential in disrupting cancer cell survival mechanisms across multiple types of cancers, including those resistant to current therapies.
The patent strengthens Akari's intellectual property portfolio and supports the development of their ADC programs, including AKTX-101 (Trop2 ADC with PH1 payload) and AKTX-102 (undisclosed target).
Akari Therapeutics (Nasdaq: AKTX) ha depositato una domanda di brevetto provvisoria presso l'USPTO per la sua nuova piattaforma di coniugato anticorpo-payload (ADC) che utilizza lo payload di spliceosoma PH1 per il trattamento del cancro. Il brevetto copre il meccanismo unico della piattaforma nel modulare l\'splicing alternativo all\'interno delle cellule tumorali.
La tecnologia mira alla capacità delle cellule tumorali di dirottare i processi di splicing alternativo (AS), che influenzano la formazione, la crescita e la metastasi dei tumori. Il payload PH1 mostra potenziale nel disrupting the survival mechanisms delle cellule tumorali in diverse tipologie di cancro, inclusi quelli resistenti alle terapie attuali.
Il brevetto rafforza il portfolio di proprietà intellettuale di Akari e supporta lo sviluppo dei loro programmi ADC, tra cui AKTX-101 (ADC Trop2 con payload PH1) e AKTX-102 (berso non divulgato).
Akari Therapeutics (Nasdaq: AKTX) ha presentado una solicitud de patente provisional ante la USPTO para su nueva plataforma de conjugado anticuerpo-payload (ADC) que utiliza la carga PH1 del spliceosoma para el tratamiento del cáncer. La patente cubre el mecanismo único de la plataforma para modular el empalme alternativo dentro de las células cancerosas.
La tecnología apunta a la capacidad de las células cancerosas para secuestrar los procesos de empalme alternativo (AS), que influyen en la formación, el crecimiento y la metástasis tumoral. La carga PH1 demuestra potencial para interrumpir los mecanismos de supervivencia de las células cancerosas en múltiples tipos de cáncer, incluidos aquellos resistentes a las terapias actuales.
La patente fortalece la cartera de propiedad intelectual de Akari y respalda el desarrollo de sus programas ADC, incluyendo AKTX-101 (ADC Trop2 con payload PH1) y AKTX-102 (objetivo no divulgado).
Akari Therapeutics(Nasdaq: AKTX)는 암 치료를 위한 신형 항체-약물접합체(ADC) 플랫폼에 대해 PH1 파이프라인 정보를 USPTO에 임시 특허 출원했다. 특허는 플랫폼의 암세포 내 대안적 스플라이싱 변화를 조절하는 독특한 메커니즘을 다룬다.
이 기술은 암세포가 대체 스플라이싱(AS) 과정을 가로채는 능력을 표적으로 삼아 종양 형성, 성장 및 전이에 영향을 준다. PH1 페이로드는 다양한 암에서 암세포의 생존 기전을 방해하는데 잠재력이 있으며, 현재 치료에 내성이 있는 암도 포함한다.
특허는 Akari의 지적 재산 포트폴리오를 강화하고 AKTX-101(PH1 페이로드를 가진 Trop2 ADC)과 AKTX-102(비공개 표적)를 포함한 ADC 프로그램의 개발을 지원한다.
Akari Therapeutics (Nasdaq: AKTX) a déposé une demande de brevet provisoire auprès de l’USPTO pour sa nouvelle plateforme d’ADC (anticorps-médicament conjugué) utilisant le payload de spliceosome PH1 pour le traitement du cancer. Le brevet couvre le mécanisme unique de la plateforme consistant à moduler l’épissage alternatif au sein des cellules cancéreuses.
La technologie vise la capacité des cellules cancéreuses à détourner les processus d’épissage alternatif (AS), qui influencent la formation tumorale, la croissance et la métastase. Le payload PH1 montre un potentiel pour perturber les mécanismes de survie des cellules cancéreuses dans divers types de cancer, y compris ceux résistants aux thérapies actuelles.
Le brevet renforce le portefeuille de propriété intellectuelle d’Akari et soutient le développement de leurs programmes ADC, y compris AKTX-101 (ADC Trop2 avec payload PH1) et AKTX-102 (cible non divulguée).
Akari Therapeutics (Nasdaq: AKTX) hat beim USPTO eine provisorische Patentanmeldung für seine neue ADC-Plattform eingereicht, die den PH1-Payload des Spliceosoms für die Krebsbehandlung nutzt. Das Patent deckt den einzigartigen Mechanismus der Plattform ab, das alternative Spleißen innerhalb von Krebszellen zu modulieren.
Die Technologie zielt darauf ab, die Fähigkeit von Krebszellen anzugreifen, alternative Splicing-Prozesse zu entführen, die die Tumorbildung, das Wachstum und die Metastasierung beeinflussen. Der PH1-Payload zeigt Potenzial dafür, Überlebensmechanismen von Krebszellen zu stören in mehreren Krebsarten, einschließlich solcher, die gegenüber aktuellen Therapien resistent sind.
Das Patent stärkt Akaris Portfolio an geistigem Eigentum und unterstützt die Entwicklung ihrer ADC-Programme, einschließlich AKTX-101 (Trop2-ADC mit PH1-Payload) und AKTX-102 (nicht offengelegtes Ziel).
قدمت شركة Akari Therapeutics (سهمها في ناسداك: AKTX) طلب براءة اختراع ابتدائية لدى USPTO لمنصتها الجديدة للربط بين الأجسام المضادة والدواء (ADC) التي تستخدم الحمولة PH1 من سلاسل سلاسل السلايسوم في علاج السرطان. تغطي البراءة آلية المنصة الفريدة في تنظيم التقطع البديل داخل خلايا السرطان.
التقنية تستهدف قدرة خلايا السرطان على استغلال عمليات التقطيع البديل، التي تؤثر على تشكيل الورم ونموه وانتشاره. تُظهر الحمولة PH1 إمكاناً في تعطيل آليات بقاء خلايا السرطان عبر أنواع متعددة من السرطان، بما في ذلك تلك المقاومة للعلاجات الحالية.
تعزز البراءة محفظة الملكية الفكرية لـ Akari وتدعم تطوير برامج ADC لديها، بما في ذلك AKTX-101 (ADC Trop2 مع الحمولة PH1) و AKTX-102 (هدف غير معلن).
Akari Therapeutics（纳斯达克股票代码：AKTX）已向美国专利商标局提交其新型抗体药物偶联物（ADC）平台的临时专利申请，该平台使用剪接体载荷PH1用于癌症治疗。该专利覆盖该平台的独特机制，即在癌细胞内调控可变剪接。
该技术瞄准癌细胞劫持可变剪接（AS）过程的能力，这些过程影响肿瘤的形成、增长和转移。PH1载荷在破坏癌细胞生存机制方面显示出潜力，覆盖多种类型的癌症，包括对现有治疗无效的癌症。
该专利加强了 Akari 的知识产权组合，并支持其 ADC 项目的开发，包括AKTX-101（带 PH1 载荷的 Trop2 ADC）和AKTX-102（未披露靶点）。
- Novel patent application extends proprietary position for PH1 payload technology
- Technology demonstrates potential effectiveness across multiple types of cancers
- Platform shows promise in targeting cancer cells resistant to current therapies
- Preclinical data shows potent cytotoxicity and robust immune cell activation
- Technology is still in early stages with no clinical trial data
- Competitive landscape in ADC development is intense
- Success in preclinical models may not translate to human trials
Insights
Akari's new patent filing strengthens IP protection for its novel cancer-fighting ADC platform that disrupts cancer's survival mechanisms.
Akari Therapeutics has filed a significant provisional patent application with the USPTO that could substantially strengthen their intellectual property position in the antibody-drug conjugate (ADC) space. The patent covers their ADC platform utilizing the novel spliceosome payload PH1 (a Thailanstatin analog) that works through a differentiated mechanism of action - modulating alternative splicing within cancer cells.
The scientific importance here lies in the approach to target alternative splicing (AS), a fundamental cellular process that cancer cells hijack to produce protein variants supporting tumor growth. By disrupting this process, Akari's technology potentially attacks cancer at a core vulnerability. The company has demonstrated that their PH1 payload can disrupt the synthesis of proteins crucial for cancer survival across multiple preclinical models.
This approach is particularly noteworthy because it targets a universal cancer mechanism rather than a single pathway. Alternative splicing affects numerous cancer hallmarks including metabolism, apoptosis evasion, cell cycle control, immune evasion, and metastasis. This gives Akari's platform potential applications across diverse cancer types, including difficult-to-treat variants like AR-v7-driven prostate cancer.
The patent filing complements existing data on PH1's potent cytotoxicity and immune cell activation capabilities, creating a more comprehensive IP portfolio around their lead program AKTX-101 (a Trop2-targeted ADC) and pipeline candidate AKTX-102. While still preclinical, this patent application represents an important milestone in Akari's strategy to develop differentiated cancer therapeutics and potentially establish partnerships that could accelerate development.
BOSTON and LONDON, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced that it has filed a provisional patent application with the United States Patent and Trademark Office (USPTO) covering the Company’s antibody drug conjugate (ADC) platform using Akari’s spliceosome payload PH1 for treating cancer by modulating alternative splicing within cancer cells. This patent application represents a new patent family to further extend Akari’s proprietary position with respect to the Company’s novel payload, PH1 (a novel Thailanstatin analog).
Abizer Gaslightwala, President and Chief Executive Officer of Akari Therapeutics commented, “These novel data included in our provisional patent application continue to demonstrate the advances in our understanding of spliceosome modulation and the growing potential of our PH1 payload to build first-in-class ADCs that work in unique ways from current options, and could potentially drive differentiated clinical outcomes and remissions for cancer patients in the future. We will continue to progress our exciting research on our spliceosome modulating payload PH1 and present evolving data and insights. This specific provisional patent application increases the scope of our intellectual property estate and enables long term value creation for Akari and potential partners we elect to work with on our ADC portfolio.”
The new application relates to how Akari’s novel PH1 payload demonstrates its ability to modulate the spliceosome to disrupt alternative splicing drivers and the subsequent synthesis of proteins needed for cancer tumors to survive and grow.
Alternative splicing (AS) leads to the production of functionally distinct protein isoforms. Cancer cells hijack this process to produce isoforms that support the "hallmarks of cancer," a set of capabilities that often tumors acquire, which contribute to the growth, proliferation, and survival of the cancer in the tumor microenvironment, and a host of other deleterious effects. Changes in AS have been linked to almost all aspects of tumor formation and cancer growth and metastasis, including changes affecting cancer cell metabolism, inhibiting apoptosis (delaying natural cell death), cell cycle control, evading the immune system, invasion of cancer cells to other tissues/organs (metastasis and spreading), and resistance of cancer cells to current therapies. Disrupting AS is a central, generalized approach to target all cancers at a fundamental level of their survival and growth, including those difficult cancers driven by specific spliced variants (i.e. AR-v7 in prostate cancer) or cancers driven by other known factors (i.e. ,VEGF, HER2, Caspase-2). This opens up the possibilities and potential for Akari to become a leader in developing therapies against a wide range of cancers utilizing spliceosome modulation using Akari’s ADC platform.
This provisional patent application is a culmination of the exciting and groundbreaking work in alternative splicing Akari is progressing with its novel ADC payload PH1. This patent also adds to the body of knowledge already established around the PH1 payload including its potent cytotoxicity and robust immune cell activation demonstrated in multiple preclinical cancer models. The Company is committed to applying this expanded knowledge around disrupting alternative splicing to advance its current ADC portfolio, consisting of AKTX-101 (Trop2 ADC with PH1 payload), as well as future programs (AKTX-102, undisclosed target with PH1 payload).
About Akari Therapeutics
Akari Therapeutics is an oncology biotechnology company developing next-generation spliceosome payload antibody drug conjugates (ADCs). Utilizing its innovative ADC discovery platform, the Company has the ability to generate ADC candidates and optimize them based on the desired application to any target of interest. Akari’s lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells and with a proprietary linker, delivers its novel PH1 payload directly into the tumor. Unlike current ADCs that use tubulin inhibitors and DNA damaging agents as their payloads, PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. This splicing modulation has been shown in preclinical animal models to induce cancer cell death while activating immune cells to drive robust and durable activity. In preclinical studies, AKTX-101 has shown to have significant activity and prolonged survival, relative to ADCs with traditional payloads. Additionally, AKTX-101 has the potential to be synergistic with checkpoint inhibitors and has demonstrated prolonged survival as both a single agent and in combination with checkpoint inhibitors, as compared to appropriate controls. The Company is generating validating data on its novel payload PH1 to continue advancing its lead asset, as well as other undisclosed targets with this novel payload.
For more information about the Company, please visit www.akaritx.com and connect on X and LinkedIn.
Cautionary Note Regarding Forward-Looking Statements
This press release includes express or implied forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, about the Company that involve risks and uncertainties relating to future events and the future performance of the Company. Actual events or results may differ materially from these forward-looking statements. Words such as “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “future,” “opportunity” “will likely result,” “target,” variations of such words, and similar expressions or negatives of these words are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. Examples of such forward-looking statements include, but are not limited to, express or implied statements regarding the ability of the Company to advance its product candidates for the treatment of cancer and any other diseases, and ultimately bring therapies to patients. These statements are based on the Company’s current plans, estimates and projections. By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific. A number of important factors, including those described in this communication, could cause actual results to differ materially from those contemplated in any forward-looking statements. Factors that may affect future results and may cause these forward-looking statements to be inaccurate include, without limitation: the Company’s need for additional capital; the potential impact of unforeseen liabilities, future capital expenditures, revenues, costs, expenses, earnings, synergies, economic performance, indebtedness, financial condition and losses on the future prospects, business and management strategies for the management, expansion and growth of the business; risks related to global as well as local political and economic conditions, including interest rate and currency exchange rate fluctuations; potential delays or failures related to research and/or development of the Company’s programs or product candidates; risks related to any loss of the Company’s patents or other intellectual property rights; any interruptions of the supply chain for raw materials or manufacturing for the Company’s product candidates, including as a result of potential tariffs; the nature, timing, cost and possible success and therapeutic applications of product candidates being developed by the Company and/or its collaborators or licensees; the extent to which the results from the research and development programs conducted by the Company, and/or its collaborators or licensees may be replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; uncertainty of the utilization, market acceptance, and commercial success of the Company’s product candidates; risks related to competition for the Company’s product candidates; and the Company’s ability to successfully develop or commercialize its product candidates. While the foregoing list of factors presented here is considered representative, no list should be considered to be a complete statement of all potential risks and uncertainties. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the SEC, copies of which may be obtained from the SEC’s website at www.sec.gov. The Company assumes no, and hereby disclaims any, obligation to update the forward-looking statements contained in this press release except as required by law.
Investor Relations Contact
JTC Team, LLC
Jenene Thomas
908-824-0775
AKTX@jtcir.com
FAQ
What is the significance of Akari Therapeutics' (AKTX) new patent filing?
How does Akari Therapeutics' PH1 payload technology work in cancer treatment?
What are the main cancer programs in Akari Therapeutics' ADC portfolio?
What advantages does Akari's PH1 payload technology offer in cancer treatment?
What types of cancers could Akari Therapeutics' technology potentially treat?
